newsfilter
← Latest News
Business Wire·

Innate Pharma Reports First Half 2026 Business Update and Financial Results

New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing completed to